Stock·NASDAQ·Healthcare
Tempus AI, Inc. (TEM)
- Market cap
- $13.16B
- Dividend yield
- None
- Street target
- $75.00median of 20 analysts
- 52-week range
- $40.77 $90.53
TEM stock forecast today
Where TEM stands today, and what CleaRank Financial AI makes of it.
TEM at a glance
Tempus AI, Inc. (TEM): Buy, 61/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($70.69 and $56.94).
- Earnings TEM beat estimates in 5 of its last 5 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $333.7M and made no open-market purchases over the last 18 months.
Figures as of October 30, 2026.
CleaRank Financial AI
CleaRank rates Tempus AI, Inc. (TEM) Buy, with a model score of 61/100.
The trend lifts the score most: the price is 26.84% above its 200-day average and 2.17% above its 50-day average, and the 50-day average is 24.15% above the 200-day. Valuation holds it back most: the company has no meaningful P/E because it lost money and the P/S of 9.19 is 170.3% above the sector median. The 50-day average stands at $70.69 and the 200-day at $56.94. Over the past year the price fell 16.29%.
Only on CleaRank
Figures we compute ourselves from TEM's own price, earnings and insider-filing history. Tap one to see it in context.
TEM stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $72.22 is 2.2% above the 50-day simple moving average of $70.69.Price above its 200-day average ›
The price is 26.8% above the 200-day simple moving average of $56.94.50-day average above the 200-day ›
The 50-day average ($70.69) is 24.1% above the 200-day average ($56.94), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 63% of its 52-week range, between $40.77 and $90.53.
TEM share price
Pick a period: each tab shows how far TEM has moved over it, to the last close.
Today's trading
Where TEM sits inside today's range and its 52-week range.
TEM fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S above the sector median ›
The price-to-sales ratio of 9.19 is 170.3% above the sector median of 3.4.Not profitable over the last 12 months ›
Net income over the last 12 months was -$254.4M on revenue of $1.4B, a net margin of -17.8%.Beat estimates in most recent reports ›
TEM beat the EPS estimate in 5 of its last 5 reports.
Key statistics
The headline figures for TEM.
As of October 30, 2026, TEM trades at $72.22, with a market value of $13.16B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of TEM's valuation, growth and risks.
TEM has no meaningful P/E, because its earnings per share over the last 12 months are negative. Its price-to-sales ratio of 9.19 is 170.3% above the sector median of 3.4. Trailing earnings stand at -$1.44 a share.
TEM is unprofitable, posting a net margin of -17.77% and an operating margin of -19.59%. Its return on equity of -67.44% is below the sector median of 7.3%. On growth it is ahead of the sector: revenue rose 21.60% year on year in the latest quarter, while the sector median was 8.1%. Debt-to-equity stands at 3.25.
TEM's latest quarterly report, dated July 30, 2026, showed -$0.04 a share, which beat the -$0.15 estimate. The share price nonetheless slipped 0.95% in the first session after the report.
The record is a clean sweep: 5 beats in 5 reports, though the stock still fell in the first session after 4 of those 5 beats. Earlier, the stock rose 12.59% after the May 6, 2025 report, a beat of 11.11%. The consensus EPS estimate stands at -$0.26 for this fiscal year and -$0.05 for next.
A typical daily move in TEM's price is 5.11%, based on the 30-day standard deviation of daily returns, and its beta against the S&P 500 is 3.54. The price is 20.23% below its 52-week high of $90.53. Over the last 18 months insiders sold $333.7M of stock and bought none on the open market. Insider sales are often planned in advance, so they carry less weight than purchases.
TEM against the Healthcare sector
How TEM compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, TEM trades at 9.19x, +170% versus the sector average of 3.40x.
Return vs XLV: Since May 20, 2025, TEM has gained 15.7% against a gain of 37.3% for XLV.
Performance against XLV
TEM and the Healthcare sector fund over the same days.
Revenue and earnings
How much TEM sells, and how much of it becomes profit.
Revenue growth: Revenue grew 83.4% in FY2025 to $1.3B, from $693M a year earlier.
Profit margin: The net margin was -19.3% in FY2025, up from -101.8% the year before.
Loss-making: TEM lost $245M in FY2025.
Earnings reality check
Did TEM beat what analysts expected, and how did the stock react?
Earnings record: TEM beat the analyst estimate in 5 of the last 5 quarters.
Market reaction: The stock fell in the first session after 4 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | -$0.15 | -$0.04 | +73.33% | -0.95% | +4.13% |
| May 5, 2026after close | -$0.20 | -$0.13 | +35.00% | -1.05% | -13.17% |
| Aug 8, 2025after close | -$0.25 | -$0.22 | +12.00% | -0.08% | +21.21% |
| May 6, 2025after close | -$0.27 | -$0.24 | +11.11% | +12.59% | +32.04% |
| Nov 4, 2024after close | -$0.31 | -$0.25 | +19.35% | -10.10% | +56.81% |
As of October 30, 2026, TEM has beaten the analyst EPS estimate in 5 of its last 5 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 30, 2026, came in 73.33% above the estimate and the stock moved -0.95% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
TEM AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 51.9, in neutral territory.RSI above 50 ›
An RSI of 51.9 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of TEM
The score, the reasoning behind it, and what could move the price next.
Tempus AI, Inc. (TEM) is in an uptrend. The price of $72.22 sits 26.84% above its 200-day average of $56.94 and 2.17% above its 50-day average of $70.69. The 50-day average is also 24.15% above the 200-day, so both averages point the same way. Over the past year, the price is 77.14% above the 52-week low of $40.77, yet 20.23% below the 52-week high of $90.53.
The short and long run point different ways: the price fell 11.82% over the past month, rose 64.62% over the past three months and fell 16.29% over the past year. Volume in the last session ran 91.4% above its average, on a day the price fell 7.22%. The 14-day RSI of 51.9 is in the neutral zone, and the MACD line is positive.
Rating reaffirmed ›
HC Wainwright & Co. kept its Buy rating on October 26, 2026.
Source: Analyst action, HC Wainwright & Co., October 26, 2026
Earnings beat, but the stock fell ›
The July 30, 2026 report beat the EPS estimate by 73.33%, and the share price fell 0.95% in the first session after it.
Source: Earnings report, July 30, 2026
- Two levels are closest to the price: the 52-week high of $90.53 above it, and the 20-day EMA of $71.04 below it.
- The 14-day RSI is 51.9, neutral, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- TEM's share price fell 0.95% in the first session after the July 30, 2026 report, even though the company has beaten estimates in 5 of the last 5 reports.
The uptrend rests on TEM staying above its 50-day average at $70.69 and its 200-day average at $56.94; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $71.04.
TEM's next level overhead is its 52-week high of $90.53.
Technical indicators
Momentum and trend for TEM, from its daily closes.
As of October 30, 2026, with TEM at $72.22, its 14-day RSI is 51.9 (neutral territory), its 50-day simple moving average is $70.69 and its 200-day is $56.94.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What TEM moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, TEM's 1-year correlation of daily returns is +0.47 with S&P 500 (SPY), +0.46 with Nasdaq 100 (QQQ), +0.31 with Bitcoin (BTC) and +0.12 with gold (XAU).
TEM price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
1/3Fewer than half of analysts rate it a buy ›
10 of 20 analysts rate it a buy or strong buy, 9 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $75.00 is 3.8% above the price.No more buy ratings than three months ago ›
10 of 20 rate it a buy now, against 8 of 16 three months ago.
TEM Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 26, 2026 | HC Wainwright & Co. | Maintains | Buy |
| Oct 26, 2026 | BTIG | Reiterates | Buy |
| Oct 23, 2026 | Needham | Reiterates | Buy |
| Oct 14, 2026 | JP Morgan | Maintains | Neutral |
| Oct 12, 2026 | Canaccord Genuity | Maintains | Buy |
| Oct 1, 2026 | Guggenheim | Maintains | Buy |
As of October 30, 2026, 20 Wall Street analysts cover TEM: 10 rate it a buy or strong buy, 9 a hold and 1 a sell or strong sell. Their 12-month price targets range from $35.00 to $100.00. The median TEM price target is $75.00, 3.8% above the price of $72.22.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
TEM trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
TEM trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
TEM moves about 5.1% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much TEM tends to move, against the market and on its own.
TEM price history and drawdowns
TEM's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/3Average daily move of 2% or more ›
The price has moved 5.11% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 59.8%, from October 2025 to July 2026; the price is still 30.1% below that peak.Beat the S&P 500 since the chart begins ›
$10,000 invested in June 2024 is now worth $17,943, against $14,333 in the S&P 500 (SPY).
TEM Drawdowns & Recovery
As of October 30, 2026, TEM's worst peak-to-trough fall over the period since June 2024 with dividends reinvested was -59.8% (October 2025 to July 2026); it is still 30.1% below that peak.
From daily closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into TEM in June 2024 is worth now, against the same amount in the S&P 500.
Against the market: TEM beat the S&P 500 over this period: $17,943 against $14,333.
A $10,000 investment in TEM in June 2024 would be worth about $17,943 today with dividends reinvested, compared with about $14,333 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
TEM stock price prediction 2028
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in TEM, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 2-year Monte Carlo simulation, based on 2.4 years of price history, projects that a $10,000 investment in TEM today could grow to about $12,050 by 2028 in the base case, with a 90th-percentile outcome near $29,824 and a 10th-percentile outcome around $4,869. Projections are statistical simulations, not guarantees.
TEM Stock Price Prediction 2028: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $87.03 for TEM by 2028 in the base case, from $72.22 today (1.2x over 2 years). The 10th-percentile path ends near $35.16. These are outcomes of a Monte Carlo simulation run on TEM's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $41.77 | $79.28 | $150 | |
| 2028 | $35.16 | $87.03 | $215 |
Method: a lognormal simulation of TEM's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
TEM insider trading
What the people running the company have bought and sold.
TEM insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought TEM shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 30, 2026, TEM insiders reported 98 open-market sales worth $333.7M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Thomas Edward Schoenherr
Officer
|
Sell | 10.3K | $873.9K |
| Sep 22, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 250.0K | $19.4M |
| Sep 1, 2026 | Ryan Fukushima
Officer
|
Sell | 30.8K | $1.9M |
| Sep 1, 2026 | Jennifer A. Doudna, PH.D.
Director
|
Sell | 676 | $44.3K |
| Sep 1, 2026 | David R Epstein
Director
|
Sell | 250 | $16.4K |
| Aug 28, 2026 | Nadja Y. West
Director
|
Sell | 3.0K | $207.0K |
| Aug 25, 2026 | Eric Paul Lefkofsky
Chairman of the Board
|
Sell | 238.2K | $16.3M |
| Aug 25, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 11.8K | $827.9K |
| Aug 21, 2026 | Ryan Fukushima
Officer
|
Sell | 14.3K | $1.0M |
| Aug 21, 2026 | Thomas Edward Schoenherr
Officer
|
Sell | 2.7K | $188.6K |
| Aug 19, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 48.8K | $2.7M |
| Aug 19, 2026 | Andrew Polovin
Officer
|
Sell | 30.1K | $1.5M |
| Aug 19, 2026 | Thomas Edward Schoenherr
Officer
|
Sell | 17.3K | $930.0K |
| Aug 18, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 132.6K | $6.6M |
| Aug 18, 2026 | Ryan Fukushima
Officer
|
Sell | 41.1K | $2.0M |
| Aug 18, 2026 | Ryan M Bartolucci
Officer
|
Sell | 6.2K | $306.3K |
| Aug 14, 2026 | Nadja Y. West
Director
|
Sell | 3.0K | $161.7K |
| Aug 12, 2026 | Ryan Fukushima
Officer
|
Grant | 62.2K | - |
| Aug 7, 2026 | Ryan Fukushima
Officer
|
Sell | 20.0K | $1.0M |
| Aug 3, 2026 | Ryan Fukushima
Officer
|
Sell | 23.8K | $1.1M |
| Aug 3, 2026 | David R Epstein
Director
|
Sell | 370 | $16.1K |
| Jul 29, 2026 | Andrew Polovin
Officer
|
Grant | 40.0K | - |
| Jul 29, 2026 | James William Rogers
Chief Financial Officer
|
Grant | 40.0K | - |
| Jul 28, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 250.0K | $10.5M |
| Jul 8, 2026 | Ryan Fukushima
Officer
|
Sell | 33.3K | $1.9M |
| Jul 6, 2026 | Ryan Fukushima
Officer
|
Sell | 10.0K | $600.0K |
| Jun 29, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $9.6M |
| Jun 25, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 11.5K | $634.1K |
| Jun 25, 2026 | Jennifer A. Doudna, PH.D.
Director
|
Sell | 2.7K | $147.0K |
| Jun 1, 2026 | David R Epstein
Director
|
Sell | 250 | $12.4K |
| May 27, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $7.8M |
| May 21, 2026 | Eric D Belcher
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Jennifer A. Doudna, PH.D.
Director
|
Grant | 5.9K | - |
| May 21, 2026 | David R Epstein
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Wayne A.i. Frederick
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Scott Gottlieb
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Theodore J Leonsis
Director
|
Grant | 5.9K | - |
| May 21, 2026 | Nadja Y. West
Director
|
Grant | 5.9K | - |
| May 19, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 22.3K | $984.3K |
| May 19, 2026 | Ryan Fukushima
Officer
|
Sell | 13.6K | $597.1K |
| May 19, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 10.9K | $478.3K |
| May 19, 2026 | Andrew Polovin
Officer
|
Sell | 8.7K | $383.5K |
| May 19, 2026 | Ryan M Bartolucci
Officer
|
Sell | 4.1K | $181.4K |
| May 19, 2026 | Thomas Edward Schoenherr
Officer
|
Sell | 1.6K | $69.6K |
| May 14, 2026 | Ryan Fukushima
Officer
|
Grant | 162.2K | - |
| May 4, 2026 | Ryan M Bartolucci
Officer
|
Grant | 24.0K | - |
| May 4, 2026 | Ryan Fukushima
Officer
|
Grant | 10.0K | - |
| May 4, 2026 | Andrew Polovin
Officer
|
Grant | 10.0K | - |
| May 4, 2026 | James William Rogers
Chief Financial Officer
|
Grant | 10.0K | - |
| May 4, 2026 | Thomas Edward Schoenherr
Officer
|
Grant | 13.6K | - |
| Apr 28, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $8.5M |
| Mar 26, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $7.7M |
| Mar 2, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 11.4K | $578.6K |
| Mar 2, 2026 | David R Epstein
Director
|
Sell | 250 | $12.7K |
| Feb 20, 2026 | Andrew Polovin
Officer
|
Sell | 19.1K | $1.1M |
| Feb 20, 2026 | Ryan M Bartolucci
Officer
|
Grant | 13.0K | - |
| Feb 20, 2026 | Ryan Fukushima
Officer
|
Grant | 75.0K | - |
| Feb 20, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Grant | 263.4K | - |
| Feb 20, 2026 | Andrew Polovin
Officer
|
Grant | 38.4K | - |
| Feb 20, 2026 | James William Rogers
Chief Financial Officer
|
Grant | 37.5K | - |
| Feb 19, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 179.8K | $10.6M |
| Feb 19, 2026 | James William Rogers
Chief Financial Officer
|
Sell | 10.1K | $595.5K |
| Feb 19, 2026 | Ryan Fukushima
Officer
|
Sell | 9.6K | $566.4K |
| Feb 19, 2026 | Erik J. Phelps
Officer
|
Sell | 9.5K | $562.5K |
| Feb 19, 2026 | Ryan M Bartolucci
Officer
|
Sell | 2.9K | $171.4K |
| Feb 2, 2026 | David R Epstein
Director
|
Sell | 370 | $22.0K |
| Jan 28, 2026 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $10.9M |
| Jan 5, 2026 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $321.3K |
| Jan 2, 2026 | Jennifer A. Doudna, PH.D.
Director
|
Sell | 1.3K | $75.2K |
| Dec 18, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $10.6M |
| Dec 16, 2025 | Erik J. Phelps
Officer
|
Sell | 1.3K | $87.8K |
| Dec 11, 2025 | James William Rogers
Chief Financial Officer
|
Sell | 20.0K | $1.5M |
| Dec 5, 2025 | Frederick Wayne
Director
|
Sell | 3.7K | $283.8K |
| Dec 1, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $378.6K |
| Dec 1, 2025 | Jennifer A. Doudna, PH.D.
Director
|
Sell | 676 | $51.1K |
| Dec 1, 2025 | David R Epstein
Director
|
Sell | 250 | $18.9K |
| Nov 25, 2025 | Ryan Fukushima
Chief Operating Officer
|
Grant | 257.0K | - |
| Nov 24, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $12.3M |
| Nov 24, 2025 | Andrew Polovin
General Counsel
|
Sell | 12.9K | $965.6K |
| Nov 20, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 183.1K | $12.6M |
| Nov 19, 2025 | Andrew Polovin
General Counsel
|
Sell | 11.6K | $775.8K |
| Nov 18, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 10.1K | $661.9K |
| Nov 18, 2025 | James William Rogers
Chief Financial Officer
|
Sell | 7.3K | $475.6K |
| Nov 18, 2025 | Erik J. Phelps
Officer
|
Sell | 3.5K | $231.5K |
| Nov 18, 2025 | Ryan M Bartolucci
Officer
|
Sell | 1.8K | $120.2K |
| Nov 11, 2025 | Jennifer A. Doudna, PH.D.
Director
|
Sell | 1.9K | $137.6K |
| Nov 3, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $445.2K |
| Nov 3, 2025 | David R Epstein
Director
|
Sell | 370 | $33.3K |
| Oct 28, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 332.5K | $29.6M |
| Oct 6, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $461.6K |
| Sep 25, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 332.5K | $25.5M |
| Sep 2, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 10.0K | $758.0K |
| Sep 2, 2025 | David R Epstein
Director
|
Sell | 250 | $18.4K |
| Aug 27, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 332.5K | $24.6M |
| Aug 26, 2025 | Theodore J Leonsis
Director
|
Sell | 20.0K | $1.5M |
| Aug 19, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 17.5K | $1.3M |
| Aug 19, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 17.5K | $1.3M |
| Aug 19, 2025 | James William Rogers
Chief Financial Officer
|
Sell | 7.5K | $562.0K |
| Aug 19, 2025 | Andrew Polovin
General Counsel
|
Sell | 5.4K | $403.0K |
| Aug 19, 2025 | Erik J. Phelps
Officer
|
Sell | 3.7K | $273.5K |
| Aug 19, 2025 | Ryan M Bartolucci
Officer
|
Sell | 1.9K | $142.1K |
| Aug 13, 2025 | Theodore J Leonsis
Director
|
Sell | 44.0K | $3.1M |
| Aug 1, 2025 | David R Epstein
Director
|
Sell | 370 | $20.4K |
| Jul 28, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 166.3K | $10.5M |
| Jul 7, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 5.0K | $300.0K |
| Jul 1, 2025 | Jennifer A. Doudna, PH.D.
Director
|
Sell | 625 | $39.1K |
| Jun 18, 2025 | Eric Paul Lefkofsky
Chief Executive Officer
|
Sell | 500.0K | $34.9M |
| Jun 16, 2025 | Erik J. Phelps
Officer
|
Sell | 51.3K | $3.7M |
| Jun 16, 2025 | Andrew Polovin
General Counsel
|
Sell | 1.4K | $102.6K |
| Jun 11, 2025 | Theodore J Leonsis
Director
|
Sell | 205.8K | $13.9M |
| Jun 3, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 20.0K | $1.2M |
| Jun 2, 2025 | Jennifer A. Doudna, PH.D.
Director
|
Sell | 558 | $30.8K |
| Jun 2, 2025 | David R Epstein
Director
|
Sell | 250 | $13.8K |
| May 20, 2025 | James William Rogers
Chief Financial Officer
|
Sell | 23.1K | $1.5M |
| May 20, 2025 | Andrew Polovin
General Counsel
|
Sell | 17.6K | $1.1M |
| May 20, 2025 | Erik J. Phelps
Officer
|
Sell | 8.4K | $531.9K |
| May 20, 2025 | Ryan Fukushima
Chief Operating Officer
|
Sell | 7.8K | $494.3K |
| May 20, 2025 | Ryan M Bartolucci
Officer
|
Sell | 6.1K | $384.0K |
| May 20, 2025 | Eric D Belcher
Director
|
Grant | 2.0K | - |
| May 20, 2025 | Jennifer A. Doudna, PH.D.
Director
|
Grant | 2.0K | - |
Source: TwelveData, from SEC Form 4 filings
TEM stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.